$AZN

Deutsche Bank ups Glencore, BHP price targets

Deutsche Bank raised price targets for Glencore (to 680p), BHP Group (to 2,900p), Anglo American (to 4,700p), Rio Tinto (to 7,600p), Antofagasta (to 3,600p), and Clarkson (to 5,800p). Other analysts adjusted targets for AstraZeneca, National Grid, M&G, AJ Bell, and Hostelworld Group.

Original reporting
Published Oct 7, 2026, 8:06 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 8:15 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$AZN
Bearish
medium confidence
Mentioned
$AZN · $RIO · $BHP · $GLCNF
Relevance
5/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$AZNBearishLow
01

Why it matters

Analyst revisions provide fresh valuation signals that can influence short‑term trading decisions.

02

Market read

Target changes affect investor sentiment on the listed companies and may prompt short‑term price moves.

03

What to watch

Macro commodity price trends and currency movements could outweigh analyst revisions.

Relevance 5/10Novelty 5/10Timing: post-market

Background

The article lists recent analyst price‑target adjustments for several FTSE‑100 and FTSE‑250 companies.

Company-level read

Ticker impact

$AZNBearishMedium confidence
Context

Bernstein cuts AstraZeneca price target, indicating a lower valuation outlook.

Expected impact

likely pressure as the market prices in the lower target

Evidence & confidence

Analyst downgrade suggests weaker future performance expectations.

$RIOBullishMedium confidence
Context

Deutsche Bank raises Rio Tinto price target, indicating a modestly higher valuation.

Expected impact

likely upside as the market prices in the higher target

Evidence & confidence

Target increase reflects better outlook.

$BHPBullishMedium confidence
Context

Deutsche Bank raises BHP Group price target, indicating a more favorable outlook.

Expected impact

likely upside as the market prices in the higher target

Evidence & confidence

Target raise reflects improved expectations.

Market effects

Analyst target revisions may shift sentiment across the mining and utilities sectors.

European markets could see modest re‑rating of listed mining and utility stocks.

Limited to investors tracking FTSE‑100 constituents.

Counterpoint

Target cuts may be over‑reactive to short‑term noise; price could rebound.

Key entities

  • Deutsche Bank Research

    Provided multiple target raises.

  • Goldman Sachs

    Issued target cuts for several stocks.

  • Bernstein

    Cut AstraZeneca target.

Related articles

$BHPMed

Shell's Refining Margin Soars to Record High After Middle East Conflict Upends Fuel Markets -- Commodities Roundup

Shell's refining margin is expected to hit a record high of $42 a barrel in Q3, up from $24 in Q2, due to Middle East conflict and fuel supply squeeze. Brent crude rose 0.6% to $101.12, while copper and gas prices also increased. U.S. ethanol production rose, and crude oil inventories fell unexpectedly. BHP agreed to sell its Kambalda nickel concentrator to Gold Fields.

$BHPMed

BHP to sell Kambalda concentrator and tenements to Gold Fields

BHP will sell the Kambalda Nickel Concentrator and related assets in Western Australia to Gold Fields, with the deal expected to close in 2027. Gold Fields plans to evaluate the site's potential for gold and nickel processing. BHP halted its WA Nickel operations in July 2024 due to global supply surplus. The sale does not include other suspended WA Nickel assets, which BHP will review by February 2027.

$AZNMed

AstraZeneca and Daiichi Sankyo to collaborate with Summit Therapeutics

AstraZeneca (AZN), Daiichi Sankyo (DSKYF), and Summit Therapeutics (SMMTF) will collaborate to test Datroway (datopotamab) with ivonescimab in multiple cancers, starting with a phase 3 trial for triple-negative breast cancer. Each company will contribute to trial costs and retain rights to their respective medicines. Ivonescimab is approved in China for NSCLC and under FDA review in the US.

Low

RIGI Approval Advances Glencore’s Argentinian Copper Hub

Glencore's MARA project in Argentina received RIGI approval, integrating the Agua Rica deposit with the Alumbrera processing plant. The company expects MARA to become a top 25 copper producer, with first production in late 2027. RIGI provides fiscal and tax stability. Glencore aims to leverage existing infrastructure to reduce costs and expedite production.